Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 2
1967 1
1968 1
1969 1
1970 2
1972 1
1974 1
1975 3
1976 1
1977 2
1978 2
1979 4
1980 3
1981 3
1982 3
1983 4
1985 5
1986 3
1987 2
1988 6
1989 6
1990 6
1991 3
1992 8
1993 8
1994 6
1995 9
1996 10
1997 13
1998 12
1999 18
2000 26
2001 37
2002 50
2003 34
2004 46
2005 54
2006 63
2007 75
2008 106
2009 102
2010 121
2011 165
2012 215
2013 219
2014 215
2015 222
2016 218
2017 199
2018 225
2019 240
2020 282
2021 272
2022 270
2023 265
2024 128

Text availability

Article attribute

Article type

Publication date

Search Results

3,565 results

Results by year

Filters applied: . Clear all
Page 1
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, Van Cutsem E, Xu RH, Aprile G, Xu J, Chao J, Pazo-Cid R, Kang YK, Yang J, Moran D, Bhattacharya P, Arozullah A, Park JW, Oh M, Ajani JA. Shitara K, et al. Among authors: oh m. Lancet. 2023 May 20;401(10389):1655-1668. doi: 10.1016/S0140-6736(23)00620-7. Epub 2023 Apr 15. Lancet. 2023. PMID: 37068504 Clinical Trial.
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.
Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, Lordick F, Van Cutsem E, Gallego Plazas J, Huang J, Shen L, Oh SC, Sunpaweravong P, Soo Hoo HF, Turk HM, Oh M, Park JW, Moran D, Bhattacharya P, Arozullah A, Xu RH. Shah MA, et al. Among authors: oh m. Nat Med. 2023 Aug;29(8):2133-2141. doi: 10.1038/s41591-023-02465-7. Epub 2023 Jul 31. Nat Med. 2023. PMID: 37524953 Free PMC article. Clinical Trial.
The lipoprotein-associated phospholipase A2 inhibitor Darapladib sensitises cancer cells to ferroptosis by remodelling lipid metabolism.
Oh M, Jang SY, Lee JY, Kim JW, Jung Y, Kim J, Seo J, Han TS, Jang E, Son HY, Kim D, Kim MW, Park JS, Song KH, Oh KJ, Kim WK, Bae KH, Huh YM, Kim SH, Kim D, Han BS, Lee SC, Hwang GS, Lee EW. Oh M, et al. Nat Commun. 2023 Sep 15;14(1):5728. doi: 10.1038/s41467-023-41462-9. Nat Commun. 2023. PMID: 37714840 Free PMC article.
RNA methylation in immune cells.
Chen Y, Oh MH, Flavell R, Li HB. Chen Y, et al. Among authors: oh mh. Adv Immunol. 2022;155:39-94. doi: 10.1016/bs.ai.2022.08.002. Epub 2022 Sep 13. Adv Immunol. 2022. PMID: 36357012 No abstract available.
3,565 results